 I've been looking for new compounds for the treatment of gastric cancer and a type of breast cancer. When you have a mutation in a cancer, it can cause an advantage in that cancer cell. So it causes it to have an increased invasiveness basically, so it can metastasise to other parts of your body and grow faster and more aggressively. Although these mutations have that advantage to cancer cells, they also come at a cost to the cancer cell. And we want to target that vulnerability, Achilles' Heal. So you have a normal cell type, which can be grown in a culture, and then the same thing with a deletion or a mutation in the particular gene, which we're interested in looking at, which is echidherin. And there's not, for gastric cancer in particular, if you have a loss of this gene, then you have four out of five chance of developing gastric cancer in your lifetime. So it's quite a large risk. So at the moment, the best treatment or the single really good treatment is to have your stomach removed, which isn't the best really. So two out of three patients will have their stomach removed and will choose that option. But a third of patients will choose to just go for a screening approach, which is the next best thing but isn't always effective. So you can quite often miss cancers through the screening approach. So we want to give them another possible outcome or choice instead of removing a stomach or instead of having a screen.